As disease flares have been reported during G-CSF treatment in patients with multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus [34,35,36], cyclophosphamide with a dose of 2–4 g/m2 is applied before G-CSF treatment with 5–10 μg/kg [27,35]. This evidence concerns the gene CSF3 and rheumatoid arthritis.